There is sound evidence that medetomidine is an effective analgesic for acute pain in sheep. In this study, 15 µg kg -1 of medetomidine was administered intravenously, and into the oesophagus, in a cross-over study, using eight sheep. Following intravenous administration, medetomidine could be detected in the plasma of these sheep for 120-180 minutes but following oesophageal administration, medetomidine could not be detected in the plasma of any sheep at any of 17 time points over four days. It is suspected that this is due to high first pass metabolism in the liver.
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Introduction
Medetomidine is an  2 -selective adrenergic agonist that has been used in veterinary medicine as a sedative, analgesic and skeletal muscle relaxant (Posner and Burns, 2009) . It is registered only for use in dogs (and cats in some countries) but it has also been investigated in horses (England and Clarke, 1996) , donkeys (Lizarraga and Janovyak, 2013) , cattle (Ranheim et al., 1999) , pigs (Sakaguchi et al., 1992) , sheep (Kästner, 2006) and a wide range of non-domestic species (Jalanka, 1989) .
In sheep, medetomidine has been shown to be an effective analgesic, especially for acute pain (Lizarraga and Chambers, 2012) .
In 1992, Chambers demonstrated that 5 µg kg -1 IV of medetomidine provided a similar level of analgesia to 15 µg kg -1 IV of fentanyl in sheep, as assessed by nociceptive threshold testing using mechanical stimulation. These sheep were apparently healthy and were not exposed to any noxious stimuli (besides the mechanical stimulation itself) at any time during this experiment. Later, Muge et al. (1994) showed that 2-7 µg kg -1 IV of medetomidine raised the nociceptive threshold of similarly non-painful sheep in a dosedependent manner. Depending on dose, this analgesic effect was detected for up to 60 minutes. In a more recent study, Murdoch et al. (2013) used osmotic pumps to demonstrate that an intraperitoneal infusion of medetomidine in sheep at 3 µg kg -1 h -1 significantly decreased pain scores for 10 hours. Moreover, this analgesia was detected independent of sedation.
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The studies by Muge et al. (1994) and Murdoch et al. (2013) show the inextricable association between the method and route of drug administration, and its duration of effect. There are a number of commercially-available orally-administered drugs for ruminants that utilise various drug delivery mechanisms to provide sustained effects. As two examples, Ivomec Maximizer® Controlled Release Capsules (Merial) and Rumensin Capsules (Elanco) are able to deliver ivermectin and monensin, respectively, into the reticulorumen for 100 days using plastic-bodied "winged" capsules with tableted cores. Methods of drug administration like these offer attractive options for the sustained-administration of analgesic drugs (e.g.  2 -agonists) to sheep.
There have been a number of studies that have reported on the pharmacokinetics and pharmacodynamics of  2 -agonists following administration into the alimentary tract in animals but the majority of these have focussed on the buccal transmucosal route of administration (Malone and Clarke, 1993; Sleeman et al., 1997; Ansah et al., 1998; Freeman and England, 1999; Ramsay et al., 2002; Slingsby et al., 2009; Gardner et al., 2010; Naples et al., 2010; DiMaio Knych and Stanley, 2011; Kaukinen et al., 2011; Vermunt et al., 2012; Hopfensperger et al., 2013) . Furthermore, a commerciallyavailable preparation of buccal transmucosal detomidine gel suitable for horses is manufactured by Orion Pharma (Orion Corporation, Finland) and is distributed by Elanco (Domosedan Gel®)
in Europe and Zoetis (Dormosedan Gel®) in USA and Australia.
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In contrast to these reports on the buccal transmucosal absorption of  2 -agonists, other publications exist that have investigated the gastrointestinal absorption of four  2 -agonists: dexmedetomidine (Proctor et al., 1991; Anttila et al., 2003) , detomidine (Devitt, 1989) , medetomidine (Vainio, 1988) and clonidine (Davies et al., 1977; Larsson et al., 2011) . We were unable to find any studies that report on the gastrointestinal bioavailability of medetomidine in sheep but the limited data available suggests that the bioavailability of  2 -agonists from the gastrointestinal system varies depending on species,  2 -agonist and the methodology of the study.
Combining all of these findings, the intriguing question can be raised as to whether an analgesic that is effective in sheep, such as medetomidine, can be delivered to sheep in a way that provides a sustained effect and is easy to administer, and additionally, is without a prohibitive suite of adverse side effects, such as excessive sedation. Our theory was that osmotic pumps containing medetomidine, administered orally to sheep, might be able to achieve these aims. Consequently, the aim of this preliminary investigation was to quantify the bioavailability of medetomidine in sheep following administration into the oesophagus.
Materials and Methods
Approval of our experimental protocol was provided by the ) IV in the opposite jugular vein at zero minutes.
At 1, 2, 4, 6, 8, 10, 15, 20, 30, 45, 60, 90, 120, 240 
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To confirm the presence of medetomidine in the preparation we used, and to determine if the urinary catheter altered the concentration of medetomidine that passed through it, diluted medetomidine (Zalopine®, diluted to 0.3 mg mL -1 using isotonic saline) was flushed through two urinary catheters into two plain glass tubes (0 h). Two more urinary catheters were filled with diluted medetomidine but samples were not collected from these catheters until 24 h later (24 h). The concentrations of medetomidine were then compared to diluted medetomidine that had not been exposed to a urinary catheter (pre-catheter).
Samples were prepared and analysed using a method of medetomidine detection that has been validated for selectivity, 
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The heart rate, respiratory rate, rectal temperature, frequency of rumen contractions, recumbency and demeanour of the sheep were also recorded. Demeanour was assessed subjectively by three veterinarians experienced in large animal medicine (THH, GCM & FRM) as being alert and responsive, quiet and responsive, mildly sedated, moderately sedated or heavily sedated. To investigate the effect that medetomidine had on heart rate and respiratory rate, data were tested for normality using a Shapiro-Wilk test and statistically significant differences between the time = 0 data points and subsequent data points were analysed using a Kruskal-Wallis
One Way Analysis of Variance (ANOVA) on Ranks.
To investigate the possibility that a low bioavailability following oesophageal administration might not be determined because the 15 µg kg -1 dose was too low, one sheep was chosen at random and was administered 50 µg kg -1 into its oesophagus as described earlier (Figure 1 ). The sheep was closely monitored for any clinical effects and then one hour later, the sheep was administered 100 µg kg -1 by the same route. Blood samples were not collected following these additional doses.
Results
The mean (SD) bodyweight of the sheep was 59 (5.9) kg and none of the sheep showed any overt signs of ill health at any stage of the study.
Plasma Both heart rate and respiratory rate data were non-normally distributed. Following intravenous administration of medetomidine, the heart rate was significantly lower (P < 0.05) than baseline (t=0) values at 4, 10, 15, 20 and 30 min (Table 1) . Respiratory rate was not significantly lower than baseline (t=0) values at any measured time point (Table 1) detected on more than one occasion but this was for less than 3.5 h.
Following oesophageal administration of medetomidine, both the heart rate and respiratory rate were not significantly different (P > 0.05) to baseline (t=0) values (Table 2) , no observable signs of sedation were seen at any time.
Discussion
The aim of this study was to investigate the bioavailability of , 1982) . For this reason, we settled on five days as a conservative length of time for our study.
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In our study, medetomidine was diluted to 0.3 mg mL -1 such that a higher volume could be administered into the oesophagus of each sheep. However, it was necessary to use a preparation of medetomidine (Zalopine®, 5 mg mL -1
) that, when undiluted, would be suitable for a low-volume osmotic pump which itself would be needed for subsequent studies if evidence of bioavailability was
shown from this route of administration.
This study is the only work we are aware of that has investigated the bioavailability of medetomidine administered into the oesophagi of sheep. Vainio (1988) reported that dexmedetomidine has an oral bioavailability of 16%
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14 but in this study, the injectable preparation was swallowed in 150 mL of water and so the possibility that some (or most) of the drug was absorbed transmucosally in the mouth cannot be excluded. It is problematic to compare the present study to the previous work performed in dogs and humans. Not only would differences be expected between species but these differences would likely be even greater when comparing omnivorous species with simple alimentary tracts (e.g. dogs and humans) to herbivorous species with alimentary tracts containing complex populations of microbiota (e.g. sheep).
The impact that ruminal contents (e.g. ingesta and microbes) had on the bioavailability of medetomidine cannot be determined from this Experiments using these methods have been performed for some time in sheep, mainly in biochemistry studies (Annison et al., 1957; Lewis et al., 1957; Bergman and Wolff, 1971) . For a more detailed
15 discussion on the factors that affect oral bioavailability, the interested reader is referred to the review by Kwan (1997) .
An in vitro study could also be considered to estimate the intrinsic hepatic clearance of medetomidine in sheep. Studies like these have been performed in herbivorous species before (Kimble et al., 2014) but results from such studies may not be clinically relevant as other factors, only seen in vivo, also influence hepatic metabolism (Iwatsubo et al., 1997) .
Our study has shown that 15 µg kg -1 of medetomidine administered into the oesophagus of sheep is inadequate to achieve detectable (above 0.2 ng mL -1 in this study) plasma concentrations. Moreover, medetomidine doses, by this route of administration of up to 100 µg kg -1 were insufficient to cause observable signs of sedation in one sheep. To further develop the concept of a slow release device/osmotic pump in the reticulorumen, we have three recommendations for future work into this area.
Firstly, higher doses of the existing preparations of medetomidine could be considered. For this, animals should be closely supervised, and supplementary oxygen and an  2 -adrengeric antagonist (atipamezole) should be available. Increasing doses could then be carefully administered to sheep to estimate the dose range required to achieve sedation by this route of administration. Sedating doses could then provide the basis for a starting dose that would be appropriate for a pharmacokinetic study.
Secondly, further work could be performed to better define the reason behind the poor bioavailability of medetomidine delivered into the oesophagus of sheep. To investigate the possibility that it was due to pre-systemic hepatic metabolism, an altered drug formulation could be considered. Two liver-bypass drug delivery systems were developed and then validated for propranolol, which has a high first-pass effect (Barnwell et al., 1992) . In this study, a 6-fold increase in the AUC and a 4-fold increase in C max were demonstrated using a mixture of unsaturated fatty acids (mainly oleic acid) and surfactants in enteric-coated liquid-filled hard gelatin capsules. Medetomidine and propranolol are both alkaline lipophilic drugs, and so the bioavailability of medetomidine by the oesophageal route may be improved using this strategy.
Thirdly, a different drug could be used. Xylazine is an  2 -agonist that is already registered for sheep (but only by injection) and may have better bioavailability than medetomidine following administration into the oesophagus. Clonidine is another  2 -agonist that could be considered. Although its pharmacokinetics, analgesic efficacy and safety have not been investigated in sheep, its reliable oral bioavailability in humans (Davies et al., 1977) makes it an intriguing option.
Conclusions
Our goal was to investigate the possibility that a recognised analgesic of sheep, medetomidine, could be administered in a way that would not require injection and could provide effects that were 
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